Nimbus Therapeutics
Nimbus Therapeutics is a biotech company dedicated to developing breakthrough medicines through precision small molecule design. They utilize a structure-based drug discovery engine, combining computational chemistry, structural biology, and molecular sciences to create potent and selective small molecule compounds. Their mission is to improve patients' lives by targeting difficult disease targets in immunology, oncology, and metabolism, with a focus on innovative, best-in-class therapies. Their approach emphasizes rigorous target selection, advanced drug discovery technologies, and efficient clinical development to deliver transformative treatments.
Industries
Nr. of Employees
medium (51-250)
Nimbus Therapeutics
Boston, Massachusetts, United States, North America
Products
HPK1 inhibitor (Phase 1/2 clinical candidate for advanced solid tumors)
Orally delivered, selective small-molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor evaluated as monotherapy and in combination with checkpoint inhibition in early-phase clinical studies; clinical and translational data include safety, immune activation and preliminary efficacy signals.
WRN (Werner syndrome helicase) inhibitor (Phase 1/2 clinical candidate for MSI‑H tumors)
Non-covalent small-molecule inhibitor of a DNA helicase intended to induce synthetic lethality in microsatellite instability–high (MSI‑H) tumors; preclinical data show potent and selective activity, robust tumor regression in MSI‑H models and advancement into first-in-human studies.
TYK2 allosteric inhibitor (clinical candidate for immune-mediated diseases)
Selective, orally active allosteric inhibitor of TYK2 pathway developed for autoimmune and inflammatory indications with clinical evaluation history and evidence of clinical activity.
Isoform-selective AMPK activators (discovery/lead optimization for metabolic disease)
Small-molecule activators targeting specific AMPK isoforms to modulate cellular energetics across tissues for metabolic and cardiometabolic indications; advanced through a research collaboration and licensing arrangement.
ACC inhibitor (clinical candidate for liver disease; program transitioned)
Liver-directed allosteric acetyl‑CoA carboxylase inhibitor advanced into clinical studies for liver disease indications, with clinical-stage pharmacodynamic and safety data; program transition noted.
Discovery-stage modulators for innate immune and kinase targets
Early discovery programs targeting innate immune sensors and kinase families with lead identification and optimization efforts to generate candidates for immune-mediated and inflammatory disorders.
HPK1 inhibitor (Phase 1/2 clinical candidate for advanced solid tumors)
Orally delivered, selective small-molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor evaluated as monotherapy and in combination with checkpoint inhibition in early-phase clinical studies; clinical and translational data include safety, immune activation and preliminary efficacy signals.
WRN (Werner syndrome helicase) inhibitor (Phase 1/2 clinical candidate for MSI‑H tumors)
Non-covalent small-molecule inhibitor of a DNA helicase intended to induce synthetic lethality in microsatellite instability–high (MSI‑H) tumors; preclinical data show potent and selective activity, robust tumor regression in MSI‑H models and advancement into first-in-human studies.
TYK2 allosteric inhibitor (clinical candidate for immune-mediated diseases)
Selective, orally active allosteric inhibitor of TYK2 pathway developed for autoimmune and inflammatory indications with clinical evaluation history and evidence of clinical activity.
Isoform-selective AMPK activators (discovery/lead optimization for metabolic disease)
Small-molecule activators targeting specific AMPK isoforms to modulate cellular energetics across tissues for metabolic and cardiometabolic indications; advanced through a research collaboration and licensing arrangement.
ACC inhibitor (clinical candidate for liver disease; program transitioned)
Liver-directed allosteric acetyl‑CoA carboxylase inhibitor advanced into clinical studies for liver disease indications, with clinical-stage pharmacodynamic and safety data; program transition noted.
Discovery-stage modulators for innate immune and kinase targets
Early discovery programs targeting innate immune sensors and kinase families with lead identification and optimization efforts to generate candidates for immune-mediated and inflammatory disorders.
Services
Structure-enabled small-molecule discovery service
End-to-end discovery service combining structural biology, computational chemistry, machine learning and medicinal chemistry to identify and optimize selective small-molecule candidates.
Translational medicine and biomarker development service
Design and implementation of PK/PD strategies, clinical assay selection and patient stratification approaches to support early clinical studies.
Preclinical pharmacology and in vivo efficacy studies
Conduct and analysis of in vivo pharmacology using xenograft, PDX and rodent disease models to evaluate efficacy and support IND-enabling packages.
Early clinical development support
Design and operational support for early-phase clinical trials including safety/tolerability assessments, pharmacokinetics, pharmacodynamics and combination study designs.
Program management and vendor/CRO contracting
Program planning, milestone tracking, vendor oversight and contract coordination to support discovery through early clinical milestones.
Structure-enabled small-molecule discovery service
End-to-end discovery service combining structural biology, computational chemistry, machine learning and medicinal chemistry to identify and optimize selective small-molecule candidates.
Translational medicine and biomarker development service
Design and implementation of PK/PD strategies, clinical assay selection and patient stratification approaches to support early clinical studies.
Preclinical pharmacology and in vivo efficacy studies
Conduct and analysis of in vivo pharmacology using xenograft, PDX and rodent disease models to evaluate efficacy and support IND-enabling packages.
Early clinical development support
Design and operational support for early-phase clinical trials including safety/tolerability assessments, pharmacokinetics, pharmacodynamics and combination study designs.
Program management and vendor/CRO contracting
Program planning, milestone tracking, vendor oversight and contract coordination to support discovery through early clinical milestones.
Expertise Areas
- Structure-based drug discovery
- Computational drug discovery and predictive ML
- Experimental structural biology (X-ray crystallography, cryo-EM)
- Medicinal chemistry and lead optimization
Key Technologies
- X-ray crystallography
- Cryo-electron microscopy
- Molecular docking and virtual screening
- Physics-based free-energy calculations